Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and NNC0480-0389 in Type 2 Diabetes
NCT05144984Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of NNC0480-0389 in type 2 diabetes mellitus (T2DM) (10 arms), sponsored by Novo Nordisk. Primary endpoint: Change From Baseline in Glycosylated Haemoglobin at 34 weeks. Started Nov 2021; status: completed.
02
Drugs
NNC0480-0389
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05144984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144984.